The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1
Open accessAbstract
Oligodeoxynucleotides containing CpG motifs (CpG ODNs) display a strong immunostimulating activity and drive the immune response toward the Th1 (T helper type 1) phenotype. These ODNs have shown promising efficacy in preclinical studies when injected locally in several cancer models. We conducted a phase 1 trial to define the safety profile of CpG-28, a phosphorothioate CpG ODN, administered intratumorally by convection-enhanced delivery in patients with recurrent glioblastoma. Cohorts of three to six patients were treated with escalating doses of CpG-28 (0.5-20 mg), and patients were observed for at least four months. Twenty-four patients entered the trial. All patients had previously been treated with radiotherapy, and most patients had received one or several types of chemotherapy. Median age was 58 years (range, 25-73) and median KPS was 80% (range, 60%-100%). Adverse effects possibly or probably related to the studied drug were moderate and consisted mainly in worsening of neurological conditions (four patients), fever above 38 degrees C that disappeared within a few days (five patients), and reversible grade 3 lymphopenia (seven patients). Only one patient experienced a dose-limiting toxicity. Preliminary evidence of activity was suggested by a minor response observed in two patients and an overall median survival of 7.2 months. In conclusion, CpG-28 was well tolerated at doses up to 20 mg per injection in patients with recurrent glioblastoma. Main side effects were limited to transient worsening of neurological condition and fever.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372 · cited 2×
“These figures compare favorably with previous trials using temozolomide, in which median survival was around six months, and one-year survival was less than 15% (Brada et al., 2001; Yung et al., 2000).”
BackgroundResultNeuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9)
Iliev, A. I., Stringaris, A. K., Nau, R., & Neumann, H. (2004) · The FASEB Journal · doi:10.1096/fj.03-0670fje · Cited by 192
Cited by
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
Toll-Like Receptor Agonists in Cancer Therapy
Adams, S. (2009) · Immunotherapy · doi:10.2217/imt.09.70 · Cited by 310
Whole Tumor Antigen Vaccines: Where Are We?
Chiang, C., Coukos, G., & Kandalaft, L. (2015) · Vaccines · doi:10.3390/vaccines3020344 · Cited by 269
Metadata
- Authors
- Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., Puybasset, L., Van Effenterre, R., Delattre, J.-Y., & Carpentier, A. F.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-01
- Volume
- 8
- Issue
- 1
- Pages
- 60-66
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2104266894
- Cited by
- 212
- References
- 4
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1. https://app.cochat.ai/papers/10.1215/s1522851705000475
- The paper
- Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., Puybasset, L., Van Effenterre, R., Delattre, J.-Y., & Carpentier, A. F. (2006). Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1. Neuro-Oncology. https://doi.org/10.1215/s1522851705000475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.